Arbutus Biopharma Corporation ABUS Increase (Decrease) in Accounts and Other Receivables

Increase (Decrease) in Accounts and Other Receivables at other companies

Southern CopperSCCO

$65.1M-81.8%

PaccarPCAR

$279.1M+20.9%

Skyline ChampionSKY

$21.77M+39.1%

Cavco IndustriesCVCO

-$15.01M—

REX American ResourcesREX

$6.92M+7.0%

CignaCI

-$2.15B-198%

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's increase (decrease) in accounts and other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's increase (decrease) in accounts and other receivables?: Arbutus Biopharma Corporation (ABUS) reported increase (decrease) in accounts and other receivables of $178.74M in Q1 2026.